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Abstract
We completed a prospective study of 164 patients involved in a Clostridium difﬁcile surveillance programme, evaluating a range of variables
such as disease severity, treatment regimen and known clinical risk factors, for their effect on case lethality. The aim of this study was to
determine if there are any additional clinical variables worth considering for inclusion in the therapeutic decision-making process. Beyond
common risk factors, secondary immunodeﬁciencies such as diabetes mellitus, malignancy, autoimmune disease, immunosuppressive
therapy and chronic hepatitis were assessed. Overall case lethality was 23%. There was a suggestion that regular proton pump inhibitor use
in past medical history might be associated with greater lethality. Immunosuppressive therapy within 1 month before the onset of diarrhoea
was associated with a signiﬁcant four-fold lethality increase. This last ﬁnding may have the potential to further improve therapeutic
judgement if used as an explicit component of a revised scoring system. In relation to Clostridium difﬁcile-associated colitis,
immunosuppressive therapy as a red ﬂag entity, as described here, has not been previously published.
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Introduction
Clostridium difﬁcile infection (CDI) remains one of the most
challenging nosocomial infections worldwide. From 1986 to
2009 in Hungary, a total of four reported CDI epidemics took
place (2001, 2003, 2004, 2009). In 2001, Urban et al. [1]
reported that out of 65 C. difﬁcile isolates, the most common
(39%) toxigenic type was PCR ribotype 087; there was no
occurrence of the binary toxin. In 2003, the same team
conﬁrmed the presence of the binary toxin in two cases out of
112 C. difﬁcile isolates; both were community-acquired infec-
tions [2]. An annual average of 43.8 CDI cases were reported
in Hungary over the years 2004–08 [3]. During those 5 years,
average morbidity was 0.4 per 100 000 population, with
average lethality at 0.9%. In 2009 and 2010, average annual
morbidity (2.1/100 000) and lethality (1.9%) ﬁgures rose to
markedly higher levels. Terhes et al. [4] detected the ﬁrst
Hungarian case of C. difﬁcile PCR ribotype 027 in a hospital
setting in 2008. In 2010, nine hospital epidemics were
registered, in three of which PCR ribotype 027 strains were
conﬁrmed [3]. Methodology guidelines in effect in Hungary as
of 2011 classify CDI as a notiﬁable disease [3]. According to
Hungary’s National Nosocomial Surveillance System data, the
number of sporadic cases in 2012 was 4506, as reported by 84
hospitals; the corresponding lethality ﬁgure was 22.3%. In
2011, the number of epidemics rose to 20, and in 2012 it was
21. However, no accurate national data on the PCR ribotype
composition of the pathogenic strains are available [5]. In a
recent Hungarian publication of ribotyping ﬁndings in 2010 and
2011, various C. difﬁcile strains isolated from patients with
diarrhoea and obtained from nationwide laboratory sources
were found to be of the 027 ribotype in 30.4% of 601, and
50.2% of 699 cases, respectively; these results demonstrate an
increasing tendency for the presence of ribotype 027 in the
country [6].
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The objective of our study was to analyse lethality risk
factors in patients presenting with CDI over the course of an
18-month observation period, with the hypothesis that there
might be extra clinical variables worth considering in thera-
peutic decision making.
Materials and Methods
Clostridium difﬁcile follow-up service
Our 1173-bed hospital with an annual throughput of 864
inpatient person-years (2012 data) set up a C. difﬁcile daily
follow-up surveillance service, the only provider to do so in
the country. From 1 January 2012 through to 1 July 2013, a
total of 164 patients have been prospectively studied by the
service. Patients were treated on the premises of the
department where they acquired the infection. Most patients
were treated by a general medical department; infections also
occurred in departments of pulmonology, urology, infectious
diseases, surgery, neurology, rheumatology and rehabilitation.
The study was approved by the hospital’s ethics committee.
Microbiological examination
Diarrhoeal faeces samples were tested using a rapid membrane
enzyme immunoassay test (Techlab, Wrexham, UK) for the
simultaneous detection of C. difﬁcile glutamate dehydrogenase
antigen and toxins A and B. For glutamate-dehydroge-
nase-positive, toxin-negative results, the protocol prescribed
a re-test of the faeces sample using a Wampole (Alere,
Waltham, MA, USA) immunoassay rapid test for toxin A and B
detection. Cases that continued to be toxin negative upon the
re-test were examined further by toxin A and B assay on
isolated C. difﬁcile (toxigenic culture). All samples that were
positive on the toxin test were also cultured for the presence
of C. difﬁcile. None of the stools positive for C. difﬁcile toxin
contained any other enteric pathogens. The surveillance
service was to be directly notiﬁed by the laboratory within
3–5 h of detecting antigen and toxin rapid test positivity in a
patient suffering from diarrhoea.
Severity score system
Current protocols recommend, as a ﬁrst choice, oral metro-
nidazole in mild/moderate CDI and oral vancomycin in severe
cases of CDI [7,8]. We assessed patients in terms of disease
severity, treatment regimen and presence of clinical risk
factors or immunosuppressed states, with the objective of
evaluating the effects of these factors on case lethality.
Working as a locum specialist in Infectious Diseases for
3 months in 2011, the lead consultant of our surveillance
service was a participating member of the C. difﬁcile surveil-
lance team of an NHS University Hospital in the UK. The
Hungarian adaptation project of their methods served as the
basis for our case severity scoring classiﬁcation system, which
was consistent with national CDI methodology guidelines
issued in 2011.
The severity score was derived from a set of six parameters
(Table 1). Severe radiological signs included intestinal disten-
sion in excess of 6 cm, ascites (unless attributable to a distinct
cause other than the colitis), and pseudomembranous colitis.
Cases were classiﬁed as mild to moderate when the total
score was 0–2, and severe when it was 3–6; in consultations,
our follow-up team recommended oral metronidazole treat-
ment for non-severe, and oral vancomycin for severe cases.
Patients were score classiﬁed by the follow-up team on a
single occasion immediately upon notiﬁcation of the diagnosis
of infection by the microbiological laboratory; therapeutic
recommendations given to department medical personnel
were based on the classiﬁcation result. Mild and moderately
severe cases were advised to be switched from ﬁrst-choice
metronidazole to vancomycin if the patient’s condition and
clinical symptoms either failed to improve within 3 days or
deteriorated. Over the course of the observation period,
neither stool transplantation nor ﬁdaxomicin treatment was
applied by our hospital.
Analysis
Unadjusted comparisons of patient subgroups were made
using Fisher’s exact tests. Multiple logistic regression analysis
was used to estimate the effects of available clinical factors on
case lethality in terms of OR. Explanatory variables included
Charlson’s index [9], a validated prognostic mortality indicator
calculated from age group and comorbidity status. Age and sex
were used as a priori adjustment variables. Factors observed to
be irrelevant were eliminated to ensure model parsimony.
Interactions between explanatory variables were explored and
included if they were signiﬁcant and clinically plausible.
TABLE 1. The severity score system applied in therapeutic
decision making on patients with Clostridium difﬁcile-associ-
ated colitis
Severity score points
White blood cell count > 15 g/L 1 point
Albumin < 25 g/L 1 point
Acute rise of creatinine level 1 point
Stool count > 6/day 1 point
Body temperature > 38.3°C 1 point
Severe grade radiological signs 1 point
Total points maximum 6 points
Score evaluation Recommended therapy
Non-severe case: 0–2 points 3 9 500 mg oral metronidazole
Severe case: 3–6 points 4 9 125 mg oral vancomycin
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Sufﬁciency of model ﬁt was checked using the Hosmer–
Lemeshow goodness-of-ﬁt test. The statistical package STATA
(version 11; StataCorp, College Station, TX, USA) was used
for data handling and analysis.
Results
Microbiological results
Antigen and toxin tests conﬁrmed positivity in all 164 patients.
In 161 patients, stool culture conﬁrmed the presence of CDI,
while culturing failed due to technical reasons in the remaining
three cases. The 027 ribotype was conﬁrmable through PCR in
a single patient, who was successfully treated and recovered
fully. Ribotyping, which current practice does not prescribe for
sporadic cases, was not performed in other patients. Over the
course of the observation period, no epidemic-level series of
CDI emerged in our hospital.
Baseline characteristics of patients
A general description of the patient group is shown in Table 2.
The male to female ratio (43.9–56.1%) was not signiﬁcantly
different across calendar years (p 0.873). As to risk factors,
130 patients (79.3%) were aged 65 years or older. Proton
pump inhibitor (PPI) treatment within 1 month before symp-
tom onset was found in the history of 96 subjects (58.5%),
evaluated against a pooled reference group of patients who
either had no history of acidity neutralizer treatment at all or
had a history of histamine 2 (H2) receptor blocker use only. A
history of antibiotic treatment before the infection was found
in 93.9% (154 out of 164) of patients. Both these risk factors
showed a decrease in frequency when comparing the two
calendar years, to a non-signiﬁcant extent (PPI from 63.3% to
51.5%; antibiotics from 96.9% to 89.4%).
A total of 26 patients (15.9%) developed a relapse, with a
lower observed incidence of such outcomes in 2013 compared
with the previous year (10.6% versus 19.9%, p 0.190).
Immunosuppressed conditions
Secondary immunosuppressed state was deﬁned as the
presence of diabetes mellitus (50 patients, 31.45%), malignancy
(32 patients, 20.13%), autoimmune disease (18 patients, 11%),
immunosuppressive therapy in recent history (within a month)
before onset of diarrhoea (13 patients, 8.18%), or chronic
hepatitis (ﬁve patients, 3.14%). With the exception of immu-
nosuppressive therapy, secondary immunosuppressive states
listed above showed no signiﬁcant association with lethality. A
concise clinical description of patients receiving immunosup-
pressive therapy is shown in Table 3. The female to male ratio
of these 13 patients was 10 : 3, and their mean age was
72.7 years. The most common primary disease of patients
receiving immunosuppressive therapy was chronic obstructive
pulmonary disease (seven patients, 54%). The treatment agent
was a steroid in all cases, with the additional risk factor of
previous antibiotic therapy being invariably present. No
patients with primary immunodeﬁciency were observed.
Mortality and risk factors
The overall case lethality in our sample was 23% (38 patients
out of 164). In 2012, 24 patients (24.5%) died, of whom four
had developed a relapse; in 2013, 14 patients (21.2%) died,
none of which were relapse cases. In all, 21 of the 38 fatalities
underwent an autopsy, which conﬁrmed pseudomembranous
colitis in seven of those patients; in one patient, the presence
of a causal relationship between CDI and the fatality could not
be fully ascertained. In the 17 patients without autopsy, the
treating physician declared a presumable causal association
between CDI and the death judging by clinical progress.
We detected a signiﬁcant interaction between treatment
regimen and case severity. The treatment regimen effect
estimates themselves were not signiﬁcant, which is probably
due to confounding by indication (Table 4). In the group of
patients treated with metronidazole, cases classiﬁed as severe
had close to 25 times the odds for death compared with
non-severe cases (OR = 24.8, 95% CI 2.6–232.8; p 0.0049).
This effect was diminished in the treatment switch group, and
was barely present in patients treated with vancomycin as a
ﬁrst choice. The adjusted effect of PPI therapy, albeit not quite
signiﬁcant, suggested about double the odds for death relative
to non-users or H2 blocker users (OR = 1.9, 95% CI 0.7–4.9;
p 0.18). Prolonged immunosuppressive therapy was estimated
to be associated with a lethality increase to more than
four-fold (OR = 4.6, 95% CI 1.2–18; p 0.025). Charlson index,
which was 6.8 points on average (SD 2.97) in the sample,
TABLE 2. Patient characteristics assessed by gender, age,
risk factors and incidence of relapses
n (%) of patients Total
p2012 2013 n (%)
All patients 98 66 164
Age
≤65 years 22 (22.5) 12 (18.2) 34 (20.7) 0.560
>65 years 76 (77.6) 54 (81.8) 130 (79.3)
Gender
Male 44 (44.9) 28 (42.4) 72 (43.9) 0.873
Female 54 (55.1) 38 (57.6) 92 (56.1)
Risk factors
Previous proton pump inhibitor 62 (63.3) 34 (51.5) 96 (58.5) 0.148
Previous antibiotic 95 (96.9) 59 (89.4) 154 (93.9) 0.091
Initial antibiotic treatment
Metronidazole 44 (44.9) 26 (39.4) 70 (42.7) 0.140
Switched to vancomycin 29 (29.6) 29 (43.9) 58 (35.4)
Vancomycin only 25 (25.5) 11 (16.7) 36 (22.0)
Relapse 19 (19.4) 7 (10.6) 26 (15.9) 0.190
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produced a highly signiﬁcant 44% increase in the odds of death
with each one-point increase.
Discussion
International and local guidelines prescribe that metronidazole
treatment is only to be chosen in the group of mild or
moderately severe cases [3,7,8]. In cases where metronidazole
therapy was started in the high (3–6) score category, the odds
of mortality were close to 25 times greater than in the
low-score group on the same treatment. The result indicates
that the use of severity scoring facilitates decision making on
initial therapy: for severe cases, i.e. those with score values 3–
6, it gives a clear indication that they must be immediately
started on vancomycin treatment. The reason why ﬁrst
treatment choices included metronidazole in the severe
disease group nevertheless is because for some patients,
therapy was started on a weekend or a holiday when the
follow-up team was not available for immediate consultancy;
also, department access to vancomycin could suffer a delay in
some cases. A further subgroup of such cases came from
occasional refusal by the treating physician to prescribe
therapy in line with the surveillance service’s recommenda-
tions. It is a limitation of our study that the ﬁrst-choice therapy
was out of line with case severity in a ﬁfth of our patients for
these reasons.
To our knowledge, there is nothing in the literature that
establishes an association between immunosuppressive ther-
apy and elevated lethality in CDI. L€ubbert et al. compared 55
CDI patients receiving immunosuppressive therapy with 50
cases without such treatment in a retrospective, controlled,
observational study [10]. Their regression analysis results
suggested a role of immunosuppressive therapy as an inde-
pendent risk factor for C. difﬁcile colitis (OR = 2.75). In our
analysis sample, patients receiving prolonged immunosuppres-
sive therapy had a signiﬁcant 4.7 times greater odds for fatality
than those without such treatment. In conclusion, immuno-
suppressive therapy before the infection might be a red ﬂag
entity that, if included in the group of risk factors underlying
the severity score, has the potential to further improve
therapeutic judgement in these high-risk cases. Further
research is required to assess independent predictive risk
factors for their effect on case lethality in CDI, with





therapy Indication of therapy
Days from treatment to
diarrhoea Comorbidity Ab
1 70 M Methylprednisolone COPD 10 None Y
2 85 F Methylprednisolone Acute bronchitis 3 DM, Hypertension Y
3 78 F Dexamethasone Brain tumour 1 Hypertension Y
4 53 F Methylprednisolone Breast cancer with lung
and bone metastases
1 Cardiomyopathy Y
5 73 F Methylprednisolone COPD 6 DM, Hypertension Y
6 65 F Methylprednisolone COPD 25 Lung cancer with bone metastases Y
7 80 F Methylprednisolone Acute bronchitis 25 Hypertension, Pacemaker implant Y
8 69 M Methylprednisolone Klatskin tumour >30 (long-term treatment) None Y
9 74 F Methylprednisolone COPD 29 DM, Pulmonary TB, Breast cancer Y
10 81 F Methylprednisolone Pulmonary ﬁbrosis >30 (long-term treatment) Hypertension, IHD Y
11 90 F Methylprednisolone COPD 14 Hypertension, IHD Y
12 53 M Methylprednisolone COPD 20 Cor pulmonale Y
13 74 F Methylprednisolone COPD 20 DM, Pulmonary TB, Breast cancer Y
Ab, antibiotics; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; F, female; IHD, ischaemic heart disease; M, male; TB, tuberculosis; Y, yes.
TABLE 4. Multiple logistic regression estimates of the effects of various factors on the odds of lethality in Clostridium
difﬁcile-associated colitis
Factor Contrast Stratum OR 95% CI p
Therapy M/V vs. M Score = 0–2 1.876 0.589–5.969 0.2869
Therapy M/V vs. M Score = 3–6 0.123 0.012–1.306 0.0821
Therapy V vs. M Score = 0–2 2.040 0.537–7.756 0.2954
Therapy V vs. M Score = 3–6 0.103 0.007–1.449 0.0920
Score 3–6 vs. 0–2 Th = M 24.830 2.648–232.841 0.0049
Score 3–6 vs. 0–2 Th = M/V 1.625 0.389–6.792 0.5058
Score 3–6 vs. 0–2 Th = V 1.257 0.171–9.256 0.8221
Charlson index +1 point All patients 1.438 1.220–1.694 <0.0001
Age +1 year All patients 1.000 0.953–1.049 0.9958
Antacid therapy PPI vs. none or H2 blocker only All patients 1.916 0.738–4.975 0.1818
Prolonged immunosuppressive therapy YES vs. no All patients 4.659 1.205–18.021 0.0258
Sex Male vs. female All patients 1.463 0.588–3.641 0.4132
M, metronidazole; V, vancomycin; Th, therapy; PPI, proton pump inhibitor; H2, histamine 2 receptor.
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special emphasis on secondary immunosuppressed states;
understanding these relationships better has the potential to
improve choice algorithms for optimum treatment.
A meta-analysis published in 2012 by Janarthanan et al.
demonstrated on observations from 300 000 patients that the
proportion of cases of CDI among PPI users was as high as
65% [11]. No comparison with H2 blockers was undertaken in
that analysis.
Another meta-analysis by Garey et al. investigated the risk
factors for CDI relapse, including acidity neutralizers. The
study conﬁrmed the risk increase associated with concomitant
use of acidity neutralizers and antibiotics in CDI; however, two
of the three studies had no subgroup differentiation, therefore
no stratiﬁed effect estimation for acidity neutralizer subgroups
was possible [12]. A systematic multicentre meta-analysis by
Tleyjeh et al. used the data of close to 202 000 patients to
provide evidence for the risks associated with H2 blockers in
CDI, primarily in a hospital setting, with concurrent antibiotic
treatment [13]. The analysis did not address the effect of H2
blockers on CDI outcomes.
To date, there is only one population-based analysis to have
studied the effects on outcomes of PPIs and H2 blockers in
CDI [14]. In that retrospective study, the effect of the two
medication types was evaluated in a pooled fashion; multiple
regression analysis adjusted for age and comorbidities revealed
no signiﬁcant relationship between acidity neutralizer treat-
ment and infection severity. A literature review and
meta-analysis of data up to and including the year 2011 by
Kwok et al. [15] revealed a possible association between PPI
use and CDI. That communication was one of those that
pointed out an additional risk increase when concomitant
antibiotic treatment was applied. However, the analysis did not
include a direct comparison of PPIs and H2 blockers in terms
of their effects on CDI; instead, it only dealt with suggestions
of side-effect control beneﬁts associated with a switch from a
PPI to a H2 blocker.
Our ﬁndings also suggest that the effects of multiple target
proton pump inhibitors—as opposed to those of single-target
H2 blockers—might represent an increased level of risk during
CDI, and may change prognosis for the worse. If this can be
conﬁrmed by future studies, it might be wise to recommend
general restrictions on continued PPI therapy in patients with
CDI, except when thorough deliberation identiﬁes such
treatment to be indispensable.
Performance assessment studies on a number of CDI
severity scoring systems are available in the literature [16,17].
Our local adaptation efforts of the system as used in the UK
should be expanded to a nationwide level in Hungary to
establish a practice of advanced and rapid professional thera-
peutic decision making in the management of patients with CDI.
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